Medical Developments International (MVP) Q4 2024 earnings summary

Executive summary

• Achieved record quarterly sales of Penthrox in Australian hospitals and record in-market demand in Europe, especially in the Nordics, France, and the UK.

• Extended UK and Ireland Penthrox distribution agreement to 2027 with improved terms.

• Implemented further business efficiencies, reducing operating costs by ~$5.0 million in FY24.

• Unaudited FY24 results in line with expectations; positive operating cashflow targeted by end of FY25.

Financial highlights

• Q4 FY24 revenue was $9.5 million; full-year revenue reached $33.2 million.

• Pain Management revenue for Q4 was $5.8 million, Respiratory $3.6 million; both segments showed strong demand.

• Gross margin improved by 5 percentage points to 74% year-over-year, driven by higher Penthrox prices and supply chain efficiencies.

• Underlying EBIT loss for FY24 was $11.6 million, a $6.6 million improvement over FY23.

• Free cashflow improved by $10.2 million year-over-year.

Outlook and guidance

• Positive momentum in margins and earnings expected to continue in FY25, with further EBIT improvement anticipated.

• Operational efficiencies of $3-4 million targeted for FY25.

• Positive operating cashflow expected by end of FY25.

• Higher Penthrox pricing in the UK, Ireland, and Australia (PBS price up 25% from August 2024) to benefit margins.